Troy J. Scott

Troy J. Scott

Auto-generated profile, based on publicly available information

Troy J. Scott

RTI International, Research Triangle Park, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2014 in Annals of the New York Academy of Sciences
Verified
Journal Article
Open access
PDF file
TSTroy J. Scott
Troy J. Scott
AOAlan C. O'COnnor
Alan C. O'COnnor
ALAlbert N. Link
Albert N. Link
TBTravis J. Beaulieu
Travis J. Beaulieu
The development of disease‐modifying treatments for Alzheimer's disease (AD) faces a number of barriers. Among these are the lack of surrogate biomarkers, the exceptional size and duration of clinical trials, difficulties in identifying appropriate populations for clinical trials, and the limitations of monotherapies in addressing such a complex multifactorial disease. This study sets out to first estimate the consequent impact on the expected cost of developing disease‐modifying treatments for AD and then to estimate the potential benefits of bringing together industry, academic, and government stakeholders to co‐invest in, for example, developing better biomarkers and cognitive assessment tools, building out advanced registries and clinical trial‐readiness cohorts, and establishing clinical trial platforms to investigate combinations of candidate drugs and biomarkers from the portfolios of multiple companies. Estimates based on interviews with experts on AD research and development suggest that the cost of one new drug is now $5.7 billion (95% confidence interval (CI) $3.7–9.5 billion) and could be reduced to $2.0 billion (95% CI $1.5–2.9 billion). The associated acceleration in the arrival of disease‐modifying treatments could reduce the number of case years of dementia by 7.0 million (95% CI 4.4–9.4 million) in the United States from 2025 through 2040.

26 July 2019 in The Journal of Technology Transfer
Verified
Journal Article
Closed access
PDF file
TSTroy J. Scott
Troy J. Scott
NVNicholas S. Vonortas
Nicholas S. Vonortas

30 September 2016 in Economics of Innovation and New Technology
Verified
Journal Article
Closed access
TSTroy J. Scott
Troy J. Scott
JSJohn T. Scott
John T. Scott
ALAlbert N. Link
Albert N. Link
This paper shows that the probability of small business firms obtaining outside financing to support their research and development projects is greater given more complex commercial opportunities – defined as a greater number of different potential applications for a project’s anticipated results – for their innovations. The effects on the probability of outside finance found for other factors are consistent with the earlier findings in the literature about innovative entrepreneurial firms.